Arcutis Biotherapeutics
ARQT
ARQT
143 hedge funds and large institutions have $797M invested in Arcutis Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 32 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
1% more funds holding
Funds holding: 141 → 143 (+2)
18% less capital invested
Capital invested by funds: $974M → $797M (-$177M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
143
Holding in Top 10
3
Calls
$3.99M
Puts
$1.13M
Top Buyers
| 1 | +$25.4M | |
| 2 | +$15.2M | |
| 3 | +$12.4M | |
| 4 |
Holocene Advisors
New York
|
+$10.2M |
| 5 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
+$9.85M |
Top Sellers
| 1 | -$20.7M | |
| 2 | -$16.3M | |
| 3 | -$10.1M | |
| 4 |
Millennium Management
New York
|
-$9.83M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.62M |